Abstract：
:Attention-deficit/hyperactivity disorder, or ADHD, is the most frequently occurring neurobiological disorder in childhood and is defined by symptoms of inattention and/or hyperactivity and impulsivity that are excessive when compared with other individuals at the same developmental level. ADHD can be successfully treated pharmacologically and stimulant medications are considered a first-line treatment. However, 20-35 % of subjects in clinical trials may have an inadequate response to initial stimulant treatment. There is no standard definition of inadequate response. In many clinical trials, response is defined as a percentage improvement on the Attention-Deficit/Hyperactivity Disorder Rating Scale alone, while in others the change in Clinical Global Impression-Improvement score has also been employed. Other outcome measures have also been used. A more meaningful definition for inadequate response is one that does not produce sufficient reduction of symptoms to produce functional improvement. The literature reveals many factors that may contribute to inadequate response to treatment. Among these are poor adherence, severity and/or complexity of ADHD, inadequate stimulant dosing and/or dose-limiting adverse effects. The reasons for poor adherence should be determined. Common factors include adverse effects, lack of effectiveness, concerns about addictive potential, difficulty ingesting the medication and cost. For patients with inadequate dosing, medication optimization should be tried. For those with dose-limiting adverse effects, switching to another stimulant class or a non-stimulant is an option. For patients who are partial responders to stimulants, despite adequate adherence and dose optimization, the addition of atomoxetine or guanfacine extended release or clonidine extended release may help them achieve adequate response.
journal_name
CNS Drugsjournal_title
CNS drugsauthors
Childress AC,Sallee FRdoi
10.1007/s40263-013-0130-6subject
Has Abstractpub_date
2014-02-01 00:00:00pages
121-9issue
2eissn
1172-7047issn
1179-1934journal_volume
28pub_type
杂志文章,评审相关文献
CNS DRUGS文献大全abstract：:Social anxiety disorder (SAD) is a prevalent and disabling disorder associated with significant co-morbidity. An increased awareness of SAD over the past two decades has given impetus to advances in the pharmacotherapeutic and psychotherapeutic treatment options for this disorder. On the basis of consistent data from ...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200519050-00002
更新日期：2005-01-01 00:00:00
abstract：:Alzheimer's disease (AD) is frequently associated with neuropsychiatric symptoms (NPS) such as agitation and aggression, especially in the moderate to severe stages of the illness. The limited efficacy and high-risk profiles of current pharmacotherapies for the management of agitation and aggression in AD have driven ...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-015-0270-y
更新日期：2015-08-01 00:00:00
abstract：BACKGROUND:The molecules that provide access to activated T cells in the CNS, including chemokines, have been considered to be a crucial step in the pathogenesis of multiple sclerosis (MS). AIMS:In this study, we investigated serial serum chemokine levels in patients with relapsing-remitting MS over 1 year and the ass...
journal_title：CNS drugs
pub_type： 杂志文章
doi：10.2165/11595060-000000000-00000
更新日期：2011-11-01 00:00:00
abstract：:Down syndrome (DS), which results from an extra copy of chromosome 21 (trisomy 21), is the most common genetically defined cause of intellectual disability. Although no pharmacotherapy aimed at counteracting the cognitive and adaptive deficits associated with this genetic disorder has been approved at present, there h...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-013-0089-3
更新日期：2013-09-01 00:00:00
abstract：BACKGROUND:Dravet syndrome (DS) is one of the most severe forms of drug-resistant epilepsy and available interventions fail to control seizures in most patients. Cannabidiol (CBD) is the first in a new class of antiepileptic drugs with a distinctive chemical structure and mechanism of action. OBJECTIVE:The aim of this...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-020-00708-6
更新日期：2020-03-01 00:00:00
abstract：OBJECTIVE:To assess the relationship between the sustained pain free (SPF) and adverse event (AE) rates associated with six oral serotonin 5-HT(1B/1D) receptor agonists (triptans) used for the treatment of acute migraine, employing data from a previous meta-analysis (that included almotriptan, eletriptan, naratriptan, ...
journal_title：CNS drugs
pub_type： 杂志文章
doi：10.2165/00023210-200721010-00006
更新日期：2007-01-01 00:00:00
abstract：:Cognitive dysfunction is a major cause of disability in patients with multiple sclerosis (MS). The prevalence of cognitive dysfunction is estimated at 45 to 65%. Natural history studies suggest that once cognitive dysfunction develops in a patient with MS, it is not likely to remit. Unlike physical disability in MS, c...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200216070-00002
更新日期：2002-01-01 00:00:00
abstract：:Given the high heritability of the disorder, attention-deficit hyperactivity disorder (ADHD) is common among parents of children with ADHD. Parental ADHD is associated with maladaptive parenting, negative parent-child interaction patterns and a diminished response to behavioural parent training. We describe our previo...
journal_title：CNS drugs
pub_type： 杂志文章
doi：10.2165/11633910-000000000-00000
更新日期：2012-09-01 00:00:00
abstract：:Methylene blue is a long-established drug with complex pharmacology and multiple clinical indications. Its diverse mechanisms of action are most likely responsible for the large variety of its clinical effects. Of interest to psychiatrists, methylene blue has antidepressant, anxiolytic, and neuroprotective properties ...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-019-00641-3
更新日期：2019-08-01 00:00:00
abstract：:Alcoholic patients suffer from harmful allostatic neuroplastic changes in the brain causing an acute withdrawal syndrome upon cessation of drinking followed by a protracted abstinence syndrome and an increased risk of relapse to heavy drinking. Benzodiazepines have long been the treatment of choice for detoxifying pat...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-015-0240-4
更新日期：2015-04-01 00:00:00
abstract：:Biopharmaceuticals can induce antibodies, which interact with and neutralize the therapeutic effect of such drugs and are therefore termed neutralizing antibodies (NAbs). In the treatment of multiple sclerosis, NAbs against interferon (IFN)-beta and natalizumab have been recognized. The prevalence of NAbs against diff...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200923050-00003
更新日期：2009-01-01 00:00:00
abstract：:Alzheimer's disease (AD) is the most prevalent dementia in the world. Its cause(s) are presently largely unknown. The most common explanation for AD, now, is the amyloid cascade hypothesis, which states that the cause of AD is senile plaque formation by the amyloid β peptide, and the formation of neurofibrillary tangl...
journal_title：CNS drugs
pub_type： 杂志文章
doi：10.1007/s40263-020-00737-1
更新日期：2020-07-01 00:00:00
abstract：BACKGROUND:Valproate is a first-line antiepileptic agent and is also used in the treatment of bipolar disorder and migraine. It is a known human teratogen. The objective of the study was to evaluate the teratogenic risk of valproate. METHODS:All callers who contacted the Israeli Teratology Information Service (TIS) be...
journal_title：CNS drugs
pub_type： 杂志文章
doi：10.2165/00023210-200822040-00004
更新日期：2008-01-01 00:00:00
abstract：:This review focuses on current information about luteal phase administration (i.e. typically for the last 2 weeks of the menstrual cycle) of pharmacological agents for the treatment of premenstrual dysphoric disorder (PMDD). Compared with continuous administration, a luteal phase administration regimen reduces the exp...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200418070-00004
更新日期：2004-01-01 00:00:00
abstract：BACKGROUND:Walking impairment is a hallmark of multiple sclerosis (MS). It affects > 90% of individuals over time, reducing independence and negatively impacting health-related quality of life, productivity, and daily activities. Walking impairment is consistently reported as one of the most distressing impairments by ...
journal_title：CNS drugs
pub_type： 杂志文章,多中心研究,随机对照试验
doi：10.1007/s40263-018-0586-5
更新日期：2019-01-01 00:00:00
abstract：:Multiple sclerosis (MS) has a profound impact on health-related quality of life (HRQoL), a comprehensive subjective measure of the patient's health status. Assessment of HRQoL informs on the potential advantages and disadvantages of disease-modifying drugs (DMDs) beyond their effects on observer-based disability and m...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-017-0444-x
更新日期：2017-07-01 00:00:00
abstract：:Schizophrenia is a long-term psychiatric disorder that impacts important mental functions and requires indefinite treatment, as well as psychosocial and economic support. The introduction of chlorpromazine, the first antipsychotic, and the subsequent development of a long list of similar dopamine-blocking antipsychoti...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-018-0588-3
更新日期：2019-01-01 00:00:00
abstract：:Several studies have found a correlation between the presence of circulating maternal autoantibodies and neuronal dysfunction in the neonate. Specifically, maternal anti-brain autoantibodies, which may access the fetal compartment during gestation, have been identified as one risk factor for developing autism spectrum...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-015-0279-2
更新日期：2015-09-01 00:00:00
abstract：:Duloxetine (Cymbalta(R)) is a potent serotonin and noradrenaline (norepinephrine) reuptake inhibitor (SNRI) in the CNS. It is indicated for the treatment of generalized anxiety disorder (GAD) as well as other indications. In patients with GAD of at least moderate severity, oral duloxetine 60-120 mg once daily was effe...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200923060-00006
更新日期：2009-01-01 00:00:00
abstract：:NEDA was evaluated as the proportion of patients free of relapses, 3-month confirmed disability progression, and free of new or newly enlarging T2 lesion and Gadolinium enhancing lesions. ...
journal_title：CNS drugs
pub_type： 已发布勘误
doi：10.1007/s40263-018-0595-4
更新日期：2019-01-01 00:00:00
abstract：:Teriflunomide is a once-daily oral agent that has been licensed in the EU since August 2013 for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS). More recently (September 2014), the EU summary of product characteristics (SmPC) was updated to include data from patients with a first cli...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-015-0299-y
更新日期：2016-01-01 00:00:00
abstract：BACKGROUND:When otherwise unexplained, syncope in patients with Alzheimer's disease may be attributed to bradycardia caused by cholinesterase inhibitors. We studied prospectively the clinical events and cardiovascular changes occurring during treatment with donepezil in patients with Alzheimer's disease. METHODS:Conse...
journal_title：CNS drugs
pub_type： 临床试验,杂志文章
doi：10.2165/00023210-200620050-00005
更新日期：2006-01-01 00:00:00
abstract：:Numerous in vitro and in vivo experimental animal studies have demonstrated that gangliosides, particularly GMI ganglioside (siagoside), may stimulate or accelerate the repair of peripheral and central nervous system neurons after various types of damage. Clinical studies of GMl in peripheral neuropathies and stroke, ...
journal_title：CNS drugs
pub_type： 杂志文章
doi：10.2165/00023210-199401030-00006
更新日期：1994-03-01 00:00:00
abstract：BACKGROUND:Diroximel fumarate (DRF) is a novel oral fumarate approved in the USA for relapsing forms of multiple sclerosis. DRF is converted to monomethyl fumarate, the pharmacologically active metabolite of dimethyl fumarate (DMF). DRF 462 mg and DMF 240 mg produce bioequivalent exposure of monomethyl fumarate and are...
journal_title：CNS drugs
pub_type： 杂志文章
doi：10.1007/s40263-020-00700-0
更新日期：2020-02-01 00:00:00
abstract：:All antipsychotics, including the atypical antipsychotics (AAPs), may cause tardive dyskinesia (TD), a potentially irreversible movement disorder, the pathophysiology of which is currently unknown. The prevention and treatment of TD remain major challenges for clinicians. We conducted a PubMed search to review the pre...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-018-0494-8
更新日期：2018-02-01 00:00:00
abstract：:This article reviews the conceptual progression in the pharmacological therapy of malignant astrocytoma (MA) over the past decade, and its future trends. It is a selective rather than an exhaustive inventory of literature citations. The experience of the Brain Tumour Cooperative Group (BTCG) and earlier phase III tria...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200115090-00005
更新日期：2001-01-01 00:00:00
abstract：:Cytomegalovirus (CMV) infection of the CNS occurs most commonly in patients with severe immunosuppression such as those with advanced HIV infection (i.e. AIDS) or those who have undergone bone marrow or solid organ transplantation. Immunocompetent patients are affected very rarely. The infection of the CNS may affect ...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200216050-00003
更新日期：2002-01-01 00:00:00
abstract：:It is difficult to determine the relative efficacy of atypical antipsychotics for the treatment of schizophrenia, based on the available literature. The purpose of this article is to review and compare the efficacy of two atypical antipsychotics: olanzapine and ziprasidone.This review focused on randomised trials in w...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200519060-00003
更新日期：2005-01-01 00:00:00
abstract：:Female hypoactive sexual desire disorder (HSDD) may occur in up to one-third of adult women in the US. The essential feature of female HSDD is a deficiency or absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty. The evaluation of female HSDD generally requ...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200216110-00003
更新日期：2002-01-01 00:00:00
abstract：:Glutamatergic, noradrenergic, serotonergic, and cholinergic systems play a critical role in the basal ganglia circuitry. Targeting these non-dopaminergic receptors remains a focus of ongoing research to improve Parkinson's disease (PD) motor symptoms, without the potential side effects of dopamine replacement therapy....
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-020-00754-0
更新日期：2020-10-01 00:00:00
